Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk Management Plans Are In Fact A “Big Deal,” FDA Tells Gilead

Executive Summary

FDA's citation of Gilead for downplaying the risk management plan for its pulmonary arterial hypertension product Letairis (ambrisentan) is noteworthy for what it doesn't cite as much for what it does

You may also be interested in...



Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning

REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.

Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning

REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.

Four Ways To Draw DDMAC's Ire: In Print, On A Dosing Card, In A Script, And In Person

In a series of letters, FDA cites Lilly, Cephalon, Bayer and Amylin for promotional violations.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel